Ming Zhou

This inventor holds 33 USPTO granted patents and 13 published patent applications, plus 6 CIPO patents and 9 EPO patents, primarily in Oligonucleotide Chemistry. Top assignees: Sarepta Therapeutics, Inc., Joyant Pharmaceuticals, Inc., Becton Dickinson and Company Limited. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ming Zhou. Retrieved from https://idiyas.com/inventor/ming-zhou-85th3a8k

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 33 (Patent Applications = 13)

% Patents Active = 60.6

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 12)

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 135(Granted Patents)

Location History:

Arlington, TX (US) (2007)
Dallas, TX (US) (2013 - 2014)
Coppell, TX (US) (2010 - 2021)
Draper, UT (US) (2020 - 2021)
Cambridge, MA (US) (2020 - 2023)
Buffalo Grove, IL (US) (2022 - 2024)

Company Filing History:

13 out of 127

Sarepta Therapeutics, Inc.

patents

11 out of 16

Joyant Pharmaceuticals, Inc.

patents

7 out of 5,420

Becton Dickinson and Company Limited

patents

4. 4 out of 5,645

The University of Texas System

Massachusetts Institute of Technology

patents

where one patent can have more than one assignee

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Oligonucleotide Analogues

Antimicrobial Inserts

Peptide Conjugates

Functionally-Modified Oligonucleotides

Thermoplastic Polyurethane

Diazonamide Analogs

Indoline Anti-Cancer Agents

Cysteine Protease Inhibitors

Magnetized Catheters

Dimeric Smac Mimetics

Methods for Preparing Diazonamides

Nonlinear Optical Filters

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12590306 - Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis (2026-03-31),

2. 12311081 - Antimicrobial inserts for medical devices (2025-05-27),

3. 12239715 - Peptide oligonucleotide conjugates (2025-03-04),

4. 11931483 - Antimicrobial inserts for medical devices (2024-03-19),

5. 11672871 - Peptide oligonucleotide conjugates (2023-06-13),

6. 11291749 - Antimicrobial inserts for medical devices (2022-04-05),

7. 11208655 - Functionally-modified oligonucleotides and subunits thereof (2021-12-28),

8. 11097011 - Peptide oligonucleotide conjugates (2021-08-24),

9. 10995175 - Thermoplastic polyurethane materials for forming medical devices (2021-05-04),

10. 10792399 - Antimicrobial inserts for medical devices (2020-10-06),

11. 10792398 - Antimicrobial inserts for medical devices (2020-10-06),

12. 10760078 - Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups (2020-09-01),

13. 10675356 - Peptide oligonucleotide conjugates (2020-06-09),

14. 10583269 - Magnetized catheters, devices, uses and methods of using magnetized catheters (2020-03-10),

15. 10344281 - Functionally-modified oligonucleotides and subunits thereof (2019-07-09),

Title: Innovations of Ming Zhou in the Field of Biomedicine

Introduction: Ming Zhou, based in Coppell, TX, is an accomplished inventor with an impressive portfolio of 25 patents. His work primarily revolves around the development of biopharmaceutical solutions targeting various medical conditions. His latest innovations continue to make significant contributions to the fields of molecular biology and therapeutic treatments.

Latest Patents: Among Ming Zhou's notable recent patents are the peptide oligonucleotide conjugates. These patents detail the composition of oligonucleotides, peptides, and peptide-oligonucleotide conjugates. The described methods focus on treating muscle diseases, as well as viral and bacterial infections, through the administration of these innovative compounds. This cutting-edge research aims to provide new therapeutic strategies for patients in need of effective medical interventions.

Career Highlights: Throughout his career, Ming Zhou has made substantial advances in biomedicine, holding key positions in reputable companies. His experience includes significant contributions at Sarepta Therapeutics, Inc. and Joyant Pharmaceuticals, Inc., where he has played an instrumental role in advancing therapeutic technologies. His work has not only led to numerous patents but has also positioned him as a leading figure in his field.

Collaborations: Collaboration is a cornerstone of scientific advancement, and Ming Zhou has partnered with notable colleagues such as Gunnar James Hanson and Qi Wei. Together, they have worked on innovative projects that leverage their collective expertise, enhancing the potential for successful biopharmaceutical developments.

Conclusion: Ming Zhou’s contributions to the realm of biomedicine through his 25 patents and collaborative efforts mark him as a distinguished inventor. His latest innovations in peptide oligonucleotide conjugates reflect his commitment to advancing medical therapies and improving patient outcomes. As he continues to drive innovation in his field, Ming Zhou stands as a testament to the power of inventive thinking and scientific collaboration.

Profile summary based on public USPTO records.